We are very happy to welcome Lauxera Capital Partners, a health tech-focused investor, that shares our passion for science, innovation, and making a real quality impact in clinical development.
This partnership marks a major milestone for us — one that will help us grow further, with the same quality, and do even more of what we believe is key – develop and deliver innovative and incisive imaging solutions that help our clients make insight-driven decisions in drug development to speed the right medicines to market.
What this means for Antaros Medical With Lauxera now part of our journey, we will continue to grow with the same drive and purpose that has guided us from the start. This partnership gives us the opportunity to focus even more on strengthening our scientific leadership in metabolism, particularly within the dynamic field of obesity; deepening our expertise in immunology and inflammation; accelerating our PET tracer development — including a proprietary fibrosis tracer now moving into clinical trials; and expanding our global reach, including strengthening our presence in the US, to support an even broader community of biopharma and biotech partners.
“Since day one, Antaros has focused on building strong science credibility, deep partnerships, and a high-quality imaging CRO capability – combining innovative imaging tools and close, collaborative partnership with sponsors,” says Richard Olbe, now appointed as CEO of Antaros Medical AB after serving as Interim CEO for a year. “This investment gives us the momentum to scale up, reach more clients, and keep pushing the boundaries of what imaging can do in clinical trials.”
A strong team moving forward We’re also excited to share a few leadership updates:
-
Richard Olbe, following a year as Interim CEO, has been appointed permanent CEO of Antaros Medical.
-
Johannes Hulthe, Co-founder, will continue as CEO of Antaros Holding
-
Lars Johansson, Co-founder, will remain in his role as Chief Scientific Officer at Antaros Medical.
“We’re incredibly proud of how far we’ve come,” says Johannes Hulthe. “Now, with Lauxera’s support, we’re ready to take the next big step — growing our impact, expanding our science, and continuing to support our clients with the best imaging solutions out there.”
Richard Olbe continues: “It’s a real privilege to take on the role of CEO at such an exciting time in Antaros Medical’s journey. The company has built an impressive foundation of scientific excellence, quality delivery, and trusted partnerships. I’m looking forward to working alongside our talented team to build on that momentum — expanding our global reach, advancing our imaging capabilities, and continuing to deliver meaningful value to our clients and their clinical development programmes.”
“At Antaros, we’ve consistently focused on advancing the use of imaging biomarkers to deepen our understanding of disease mechanisms,” Lars Johansson adds. “To continue pushing the boundaries of innovation, we saw the need for additional resources to further develop next-generation imaging techniques and expand into new therapeutic areas.”
A partnership built on shared vision “We are thrilled to partner with Antaros’ talented team to support their next phase of growth,” says Alex Slack, Co-Founder at Lauxera Capital Partners. “Their unique combination of scientific excellence and operational execution makes them a standout partner for innovative biopharma companies seeking unique insights in drug development.”
Victor Decrion, Managing Partner at Lauxera Capital Partners, added: “Antaros’ unmatched expertise in metabolism — including obesity, fibrosis, cardiometabolic, and renal diseases — provides a strong platform for continued innovation into new therapeutic areas like oncology, immunology, and neurology. On top of this exceptional base, we plan to bring new perspectives, additional industry expertise, and Lauxera’s resources to further accelerate Antaros’ growth and scale it to one of the leading global imaging CROs.”
Complementing the Lauxera team, Antaros is also welcoming three new industry leaders to the company’s Board of Directors. Their insights and experience will be immensely valuable to Antaros in the journey ahead:
-
Jean-Philippe Milon, former executive at Bayer, Parexel, and Intuitive Surgical.
-
James Cornwall, former executive at GSK, Quintiles, and current Head of Business Development at Launch Therapeutics
-
Matt Silva, former executive at InviCRO, Vertex, and Takeda, and current CEO of Emit Imaging
We are all truly excited about what’s ahead and grateful to all our colleagues, partners, and clients who’ve helped us get here. Stay tuned — the next chapter of Antaros Medical is just getting started!